SCHEMBL1006776

SCHEMBL1006776

Nc1cc(F)cc(C(=O)O)c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.57
MMP2 P08253 1/20 0.48
ALDH1A1 P00352 4/20 0.46
TDP1 Q9NUW8 4/20 0.46
HSD17B10 Q99714 4/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
AKR1C2 P52895 3/20 0.42
AKR1C1 Q04828 3/20 0.42
KDM4E B2RXH2 6/20 0.41
KMT2A Q03164 4/20 0.41
HCAR1 Q9BXC0 1/20 0.41
GFER P55789 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MAPT P10636 3/20 0.39
MEN1 O00255 3/20 0.39
CYP3A4 P08684 3/20 0.39
THRB P10828 2/20 0.39
RECQL P46063 2/20 0.39
AKR1C4 P17516 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9654573 0.87 KEAP1 (0.45) KEAP1MMP2ALDH1A1TDP1HSD17B10
SCHEMBL27866235 0.83 PARP1 (0.43) KEAP1MMP2ALDH1A1HSD17B10KDM4E
SCHEMBL7628578 0.82 KEAP1 (0.41) KEAP1MMP2ALDH1A1KDM4EKMT2A
SCHEMBL27819480 0.81 KEAP1 (0.59) KEAP1MMP2ALDH1A1TDP1HSD17B10
SCHEMBL1888280 0.81 KEAP1 (0.59) KEAP1MMP2ALDH1A1TDP1HSD17B10
Hydrochloric Acid SCHEMBL9064648 0.79 KEAP1 (0.57) KEAP1MMP2ALDH1A1TDP1HSD17B10
SCHEMBL21750061 0.79 KEAP1 (0.57) KEAP1MMP2ALDH1A1TDP1HSD17B10
SCHEMBL2791251 0.78 AKR1C2 (0.58) KEAP1ALDH1A1TDP1HSD17B10AKR1C2
SCHEMBL30692478 0.78 MMP2 (0.52) KEAP1MMP2ALDH1A1TDP1HSD17B10
SCHEMBL2192034 0.78 TDP1 (0.63) KEAP1MMP2ALDH1A1TDP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492370-B2 Compounds and methods for their production BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-23 US disclosed
EP-1973883-B1 NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2012-07-11 EP disclosed
US-20110160175-A1 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer MARTIN CHRISTINE 2011-06-30 US disclosed
US-20110021481-A1 Novel Compounds and Methods for Their Production BRISTOL-MYERS SQUIBB COMPANY 2011-01-27 US disclosed
EP-2277870-A1 Substituted benzoxa(thia)zoles Bayer CropScience AG (DE) 2011-01-26 EP disclosed
EP-2277870-A1 Substituted benzoxa(thia)zoles Bayer CropScience AG (DE) 2011-01-26 EP disclosed
WO-2010149308-A2 SUBSTITUTED BENZOXA (THIA) ZOLES BAYER CROPSCIENCE AG (DE) 2010-12-29 WO disclosed
WO-2010149308-A2 SUBSTITUTED BENZOXA (THIA) ZOLES BAYER CROPSCIENCE AG (DE) 2010-12-29 WO disclosed
WO-2008056189-A1 18, 21-DIDESOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER BIOTICA TECHNOLOGY LIMITED (GB) 2008-05-15 WO disclosed
WO-2008056188-A2 NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION BIOTICA TECHNOLOGY LIMITED (GB) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160175-A1 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer BCL3, CD22, MEN1 KEAP1 980/4885MMP2 3354/4885ALDH1A1 2496/4885
US-20110021481-A1 Novel Compounds and Methods for Their Production BCL6, BCL3, AQP4 KEAP1 265/4885MMP2 2186/4885ALDH1A1 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.